LifeMD appoints Harvard clinicians to board of directors



NEW YORK – LifeMD, Inc. (Nasdaq: LFMD), a provider of virtual primary care services, today announced that Dr. Calum MacRae has joined its Board of Directors. Dr. MacRae, an experienced clinician and researcher affiliated with Harvard Medical School, will bring his expertise in cardiology, internal medicine and clinical innovation to the company.

Dr. MacRae's appointment is seen as a strategic move for LifeMD as the company aims to strengthen its virtual healthcare offerings, particularly in managing chronic conditions. LifeMD Chairman and CEO Justin Schreiber expressed enthusiasm for Dr. MacRae's experience with at-home tools and labs that could revolutionize chronic disease and preventive care.

Focused on translating research findings into clinical practice, Dr. MacRae has held several prestigious positions in the medical field. He is vice chair for scientific innovation in the Division of Medicine at Brigham and Women's Hospital, professor of medicine at Harvard Medical School, and has affiliations with the Broad Institute of Harvard and MIT and the Harvard Stem Cell Institute. His research explores cardiovascular disease biology and genomics.

Dr. MacRae's leadership in the One Brave Idea initiative, which looks at how technology can inform disease management, and his role as principal investigator for heart and exercise research at Apple Inc. The promise of technology and biomedicine. He has also consulted for several pharmaceutical and technology companies and co-founded health-related ventures.

LifeMD operates a vertically integrated digital care platform that provides telemedicine, laboratory and pharmacy services. It covers more than 200 conditions, including men's and women's health, weight management and hormonal treatments. The company's goal is to provide convenient, quality and affordable care across the United States.

3rd party advertising. Not an offer or recommendation by Investing.com.See disclosures here or
Remove ads
.

The information in this article is based on a LifeMD, Inc. press release.

Investment Professional Insights

As LifeMD, Inc. (NASDAQ: LFMD) continues to expand its board of directors, adding major industry players, investors and stakeholders are paying close attention to the company's financial health and market performance. With the appointment of Dr. Calum MacRae, LifeMD is poised to further its commitment to integrating advanced technology into health care delivery. Recent indicators and InvestingPro Tips provide a more comprehensive view of LifeMD's market position and investment potential.

InvestingPro's data highlights LifeMD's impressive gross margin, which stood at 87.61% for the trailing twelve months ended in the fourth quarter of 2023. a key aspect of the industry. Additionally, LifeMD demonstrated solid returns last week, with a total price return of 19.5%, reflecting investor confidence in strategic moves such as Dr. MacRae's appointment.

In addition, LifeMD's revenue has grown strongly, growing 59.53% as of the fourth quarter of 2023. While LifeMD has modest debt levels, it is also trading near its 52-week high and is currently 99.17% of that peak, which may indicate strong market sentiment towards the company's shares.

Investors interested in a more in-depth analysis can explore other InvestingPro Tips, which include insights into LifeMD's performance over different time frames and its valuation multiples. LifeMD, for example, wasn't profitable in the last 12 months and has a high price-to-book ratio of 137.62, which may be a consideration for value-focused investors. LifeMD also provides more than 10 additional InvestingPro tips to give you a nuanced understanding of a company's financial health and market dynamics.

3rd party advertising. Not an offer or recommendation by Investing.com.See disclosures here or
Remove ads
.

For those looking to take advantage of these insights, remember to use the exclusive coupon code PRONEWS24 Get an additional 10% discount on annual or two-year Pro and Pro+ subscriptions at InvestingPro. The product provides investors with a comprehensive toolkit to help them make informed decisions in the rapidly evolving digital healthcare space.

This article was generated with the support of artificial intelligence and reviewed by an editor. For more information, please see our terms and conditions.





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *